NEW YORK (GenomeWeb News) – TrovaGene today confirmed it has regained ownership of worldwide rights and control of its patent estate for transrenal technology for non-invasive prenatal applications and cancer after terminating a licensing deal with Sequenom.
TrovaGene, formerly known as Xenomics, licensed several patents covering prenatal diagnostic and screening applications to Sequenom in 2008 on an exclusive basis, but in 2009 it sued Sequenom alleging it fraudulently misrepresented the status of its Down Syndrome test.
The case was thrown out by US District Court of the Southern District of New York in May 2010, which ruled that under the companies' licensing deal, any dispute arising from the agreement had to be resolved first by arbitration, Sequenom said in a statement announcing its first-quarter 2010 results last year.
Neither company has since disclosed any information about the dispute or its possible resolution.
Today, Thomas Adams, chairman of TrovaGene, said that regaining the technology rights "gives us the opportunity to expand our business in the women's healthcare market beyond our advanced HPV screening program based on urine samples."
The San Diego company added that it has used next-generation sequencing to generate data "that unambiguously demonstrated the plurality and genomic representation of fetal transrenal sequences in urine from pregnant women."
The company has begun discussions with unnamed partners "whose analytical technologies are synergistic to short transrenal DNA fragments in urine, complementing its proprietary nucleic acid extraction and processing methodologies."